Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Related Press Releases
![Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
![Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
![Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
![Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
![Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
![Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
![Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
![Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
![Ipsen appoints Keira Driansky as EVP, President of North America Ipsen appoints Keira Driansky as EVP, President of North America](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)